Scinai Immunotherapeutics Ltd. · NASDAQ:SCNI
Scinai Immunotherapeutics — BiondVax Pharmaceuticals — Investor Presentation (December 2021)
8 slides from Scinai Immunotherapeutics's investor presentation, Dec 13, 2021
Slide 1: Amir Reichman, CEO – December 2021
AMIR REICHMAN, CEO NASDAQ: BVXV | DECEMBER 2021
Slide 2: Forward-looking statements disclaimer
2 This communication is not a prospectus or offer of securities for subscription or sale in any jurisdiction. This communication contains forward - looking statements within the meaning of the Private Litigation Reform Act of 1995 . Words such as “expect,” “believe,” “intend,” “plan,” “continue,” “m
Slide 3: Well positioned to bring innovative therapies to market
3 WELL POSITIONED TO BRING INNOVATIVE THERAPIES TO MARKET A small pharma company with BIG pharma capabilities: Top - tier pharma leadership Collaboration * with Max Planck & UMG GMP manufacturing facility Extensive development expertise to phase 3 results * Term sheets signed October 19, 2021. Final
Slide 4: Creating an innovative VHH pipeline
4 CREATING AN INNOVATIVE VHH PIPELINE Extending from a promising COVID - 19 therapeutic … • Validated targets of existing mAb treatments • Short time to value generation, lower risk than mAbs • Large markets growing at attractive CAGRs COVID 19 Lead candidate demonstrating strong competitive edge (
Slide 5: The VHH value proposition
5 THE VHH VALUE PROPOSITION Multiple crucial advantages compared to monoclonal antibodies (mAbs) • Superior specificity & binding affinity – can increase efficacy • Small size reaches targets mAbs cannot reach • Lower immunogenicity INTRINSIC ADVANTAGES BROAD CLINICAL POTENTIAL CONVENIENT AND FLEXIB
Slide 6: COVID treatment candidate has a strong competitive edge
6 “ Neutralization of SARS - CoV - 2 by highly potent, hyperthermostable , and mutation - tolerant nanobodies ” COVID TREATMENT CANDIDATE HAS A STRONG COMPETITIVE EDGE EMBO J (2021) 40: e107985 https://doi.org/10.15252/embj.2021107985 • Superior affinity - 100 x stronger in - vitro neutralization vs
Slide 7: Current market sizes and timeline
7 €2.6B asthma € 10.4 B psoriasis € 5.0 B macular degeneration € 4.5 B psoriatic arthritis TIMELINE INITIAL FOCUS * Sources: D atamonitor ; Fiercepharma ; L. E. K. research and analysis Execution of final agreements • Proof of concept (COVID) • Initiate development toward potential future targets •
Slide 8: Significant potential for value creation
SIGNIFICANT POTENTIAL FOR VALUE CREATION Well - positioned to bring innovative therapies to market with unique large pharma competencies Strategic collaboration with world - renowned Max Planck Institute* Targeting large addressable markets with a pipeline of VVH antibodies Lead candidate to treat C
BiondVax Pharmaceuticals — Investor Presentation (December 2021) on 6ix